A recent study highlights both the promise and limitations of the inhaled COVID-19 vaccine Ad5-XBB.1.5. Researchers found that the vaccine effectively induced strong immunoglobulin A (IgA) responses in the nasal mucosa and bloodstream, with nasal IgA showing a stronger correlation with virus-neutralizing activity than immunoglobulin G (IgG). The vaccine also boosted antigen-specific CD8⁺ T cell responses and slightly increased antibody-dependent cellular phagocytosis (ADCP). However, the study revealed that nasal IgA levels declined significantly by six months post-vaccination, and the majority of participants experienced breakthrough infections during the recent JN.1 wave. Additionally, individuals with high levels of pre-existing antibodies against adenovirus type 5 (Ad5) showed reduced neutralizing responses, indicating that vector immunity may limit the vaccine’s effectiveness. These findings underscore the challenges of achieving long-lasting mucosal immunity through current inhaled vaccine strategies. The researchers call for the development of next-generation mucosal vaccines, that can sustain strong and durable IgA responses in the nasal mucosa, offering better protection against emerging SARS-CoV-2 variants and reducing community transmission.

Cataracts are a leading cause of vision loss worldwide, and fibrosis-related complications after surgery often limit full recovery. 

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer (NSCLC).

A naturally occurring metabolic compound, pyruvate, has been identified as a potent suppressor of inflammation in ulcerative colitis (UC), offering a promising new strategy for treating this chronic bowel disease.